ArticleTranslational gastroenterology and hepatology2025
Higher waist circumference as a risk factor for rebleeding of small bowel angiodysplasia.
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent bleeding from small bowel angiodysplasia (SBA) is common, and identifying risk factors for rebleeding can help identify high-risk patients who may benefit from further therapy. The pathophysiology of SBA is linked to an imbalance of angiogenic factors such as angiopoietin 1 (Ang-1) and angiopoietin 2 (Ang-2), as well as higher serum levels of Ang-2. Additionally, murine models of steatohepatitis showed elevated serum and hepatic Ang-2 levels, which directly promote pathological angiogenesis. The present study aimed to evaluate risk factors for rebleeding in symptomatic patients with SBA. Methods: Upon review of the medical records and application of the inclusion and exclusion criteria, 109 cases were determined to be affected by SBAs. Five patients were ineligible for the study because of a shorter than one-year follow-up period or early use of a specific treatment. Thus, in a retrospective observational study of 104 patients with gastrointestinal bleeding from SBA between 2012 and 2016 who were conservatively managed at the beginning of follow-up, we obtained clinical features and risk factors for rebleeding, and we analyzed potential predictors of rebleeding through univariate and multivariable analysis. Results: We found that 57 of 104 patients (54.8%) experienced rebleeding during a follow-up of more than one year. The majority were females (71.2%), and we noted that hypertension (70.2%) and dyslipidemia (43.3%) were the most common comorbidities. Multiple regression analysis indicated that waist circumference (WC) (odds ratio for each 1 cm increment =1.04; 95% confidence interval: 1.01-1.08; P=0.02) was a significant risk factor for rebleeding. Conclusions: In patients with symptomatic SBAs, an increase in WC positively correlated with the risk of rebleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.